Evidence map›Paper›PMID 29396588›Full record

ArticleApplied microbiology and biotechnology2018

Identification of cyclosporin C from Amphichorda felina using a Cryptococcus neoformans differential temperature sensitivity assay.

Lijian Xu, Yan Li, John B Biggins, Brian R Bowman, Gregory L Verdine, James B Gloer, J Andrew Alspaugh, Gerald F Bills

Open access · greenAbstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Cyclodepsipeptide Biosynthesis inPathogens (Basel, Switzerland) · 2020
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Lijian XuTexas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, 1881 East Road, 3SCR6.4676, Houston, TX, 77054, USA.
Yan LiTexas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, 1881 East Road, 3SCR6.4676, Houston, TX, 77054, USA.
John B BigginsLifeMine Therapeutics, 430 E. 29th Street, Suite 830, New York, NY, 10016, USA.
Brian R BowmanLifeMine Therapeutics, 430 E. 29th Street, Suite 830, New York, NY, 10016, USA.
Gregory L VerdineLifeMine Therapeutics, 430 E. 29th Street, Suite 830, New York, NY, 10016, USA.
James B GloerDepartment of Chemistry, University of Iowa, Iowa City, IA, 52242, USA.
J Andrew AlspaughDepartments of Biochemistry and Medicine, Duke University Medical Center, Durham, NC, 27710, USA.
Gerald F BillsTexas Therapeutics Institute, The Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, 1881 East Road, 3SCR6.4676, Houston, TX, 77054, USA. billsge@vt.edu.ORCID http://orcid.org/0000-0003-2352-8417
Brown Foundation · USDuke Medical Center · USInstitute of Vegetables and Flowers · CNUniversity of Iowa · US

Funding

Mining the Coprophilous Mycobiome for New Cryptococcus Antiinfectives and Antifungal SynergistsR01GM121458 · NIGMS · UNIVERSITY OF IOWA · PI ALSPAUGH, ANDREW, AN, ZHIQIANG · 2017 to 2020
$2.1M
National Institute of General Medical Sciences R01 GM121458NIGMS NIH HHS R01 GM121458
6 · The paper itself

Abstract

We used a temperature differential assay with the opportunistic fungal pathogen Cryptococcus neoformans as a simple screening platform to detect small molecules with antifungal activity in natural product extracts. By screening of a collection extracts from two different strains of the coprophilous fungus, Amphichorda felina, we detected strong, temperature-dependent antifungal activity using a two-plate agar zone of inhibition assay at 25 and 37 °C. Bioassay-guided fractionation of the crude extract followed by liquid chromatography-mass spectrometry (LC-MS) and nuclear magnetic resonance spectroscopy (NMR) identified cyclosporin C (CsC) as the main component of the crude extract responsible for growth inhibition of C. neoformans at 37 °C. The presence of CsC was confirmed by comparison with a commercial standard. We sequenced the genome of A. felina to identify and annotate the CsC biosynthetic gene cluster. The only previously characterized gene cluster for the biosynthesis of similar compounds is that of the related immunosuppressant drug cyclosporine A (CsA). The CsA and CsC gene clusters share a high degree of synteny and sequence similarity. Amino acid changes in the adenylation domain of the CsC nonribosomal peptide synthase's sixth module may be responsible for the substitution of L-threonine compared to L-α-aminobutyric acid in the CsA peptide core. This screening strategy promises to yield additional antifungal natural products with a focused spectrum of antimicrobial activity.

Indexed as

Antifungal AgentsCryptococcus neoformansCyclosporinsHypocrealesTemperatureAntifungal Agentscyclosporin CCyclosporinsAdenylation domainAntifungalAscomycotaCoprophilous fungiGenomeHypocrealesNonribosomal peptide synthetaseSecondary metabolitesThermal adaption

Identifiers

PMID29396588
PMCPMC5942556
OpenAlexW2786441497

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.